Ridgetech Inc., a wholesale distributor of pharmaceutical and healthcare products in China, reported its financial results for the fiscal year ending March 31, 2025. The company experienced a revenue decrease of $4.02 million, or 3.2%, totaling $119.97 million, compared to $123.99 million in the previous year. This decline was attributed to a $5.13 million, or 4.3%, decrease in revenue from offline wholesale activities. Despite the revenue drop, Ridgetech recorded a net income of $10.20 million, a significant turnaround from the net loss of $4.23 million reported for the previous fiscal year. Earnings per share stood at $1.84 for both basic and diluted earnings, compared to a loss of $2.93 per share last year. The gross margin for the fiscal year was 3.2%, a decrease from 3.9% in the prior year. Operating margin shifted to (0.9)% from 0.5% the previous year. The company's cash and cash equivalents increased significantly to $12.78 million from $2.30 million as of March 31, 2024. Ridgetech's strategic transformation included the acquisition of Ridgeline and its subsidiary, Allright (Hangzhou) Internet Technology Co. Ltd, marking an expansion into both online and offline distribution channels. Revenue from Allright's platforms contributed nearly 1% to total revenue with a gross margin of 7.4%. Looking ahead, Ridgetech expressed confidence in its position to drive long-term sustainable growth and improved financial performance by continuing the integration of its business segments and resources.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.